ArticleClinical cancer research : an official journal of the American Association for Cancer Research2009
Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.European urology · 2015Pooled it
- Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature.Korean journal of urology · 2014Pooled it
- A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.The Journal of urology · 2011Trial
- [Active surveillance of prostate cancer : An update].Der Urologe. Ausg. A · 2019Article
- Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study.Journal of Korean medical science · 2018Article
- Biomarkers for prostate cancer: present challenges and future opportunities.Future science OA · 2016Review
- Epithelial-mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure.The Prostate · 2015Article
- Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate Cancer.BioMed research international · 2015Review
- Circulating biomarkers for discriminating indolent from aggressive disease in prostate cancer active surveillance.Current opinion in urology · 2014Review
- Emerging PSA-based tests to improve screening.The Urologic clinics of North America · 2014Review
- A panel of DNA methylation markers reveals extensive methylation in histologically benign prostate biopsy cores from cancer patients.Biomarker research · 2014Article
- Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management.Prostate international · 2014Article
- Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer.American journal of clinical and experimental urology · 2014Review
- Future prospects in the diagnosis and management of localized prostate cancer.TheScientificWorldJournal · 2013Review
- Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.The Journal of urology · 2012Article
- Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics.Asian journal of andrology · 2012Review
- A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy.Oncology letters · 2012Article
- Article
- Distribution and associations of [-2]proenzyme-prostate specific antigen in community dwelling black and white men.The Journal of urology · 2012Article
- Tumor markers in prostate cancer I: blood-based markers.Acta oncologica (Stockholm, Sweden) · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
purposeWe assessed the association of quantitative clinical and pathologic information, including serum and tissue pro-prostate-specific antigen (proPSA) measurements, with outcomes among men with prostate cancer in an expectant management (active surveillance) program. EXPERIMENTAL
designWe identified 71 men enrolled in expectant management with frozen serum and tissue available from diagnosis: 39 subsequently developed unfavorable biopsies (Gleason score > or =7, > or =3 cores positive for cancer, >50% of any core involved with cancer), whereas 32 maintained favorable biopsies (median follow-up, 3.93 years). Serum total PSA, free PSA (fPSA), and [-2]proPSA were measured by the Beckman Coulter immunoassay. [-5/-7]proPSA was evaluated in cancer and benign-adjacent areas (BAA) by quantitative immunohistochemistry. Cox proportional hazards and Kaplan-Meier analyses were used to identify significant associations with unfavorable biopsy conversion.
resultsThe ratio [-2]proPSA/% fPSA in serum was significantly higher at diagnosis (0.87 +/- 0.44 versus 0.65 +/- 0.36 pg/mL; P = 0.02) in men developing unfavorable biopsies. [-5/-7]proPSA tissue staining was more intense (4104.09 +/- 3033.50 versus 2418.06 +/- 1606.04; P = 0.03) and comprised a greater fractional area (11.58 +/- 7.08% versus 6.88 +/- 5.20%; P = 0.01) in BAA of these men. Serum [-2]proPSA/% fPSA [hazard ratio, 2.53 (1.18-5.41); P = 0.02], BAA [-5/-7]proPSA % area [hazard ratio, 1.06 (1.01-1.12); P = 0.02] and BAA [-5/-7]proPSA stain intensity [hazard ratio, 1.000213 (1.000071-1.000354); P = 0.003] were significantly associated with unfavorable biopsy in Kaplan-Meier and Cox analyses. Serum [-2]proPSA/% fPSA significantly correlated with BAA [-5/-7]proPSA % area (rho = 0.40; P = 0.002) and BAA [-5/-7]proPSA stain intensity (rho = 0.33; P = 0.016).
conclusionsIn a prospective cohort of men enrolled into expectant management for prostate cancer, serum and tissue levels of proPSA at diagnosis are associated with need for subsequent treatment. The increase in serum proPSA/% fPSA might be driven by increased proPSA production from "premalignant" cells in the prostate BAA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.